The public has bombarded the National Institute for Health and Clinical Excellence (NICE) with messages asking them to rethink their guidance to limit the use of sight saving drugs.
In draft proposals, NICE have recommended that two drugs to treat age related macular degeneration (AMD), Lucentis and Macugen, not be made widely available on the NHS.
The Royal National Institute of Blind People (RNIB) want NICE to propose that both drugs be funded in England and Wales.
Head of Campaigns at the RNIB Steve Winyard says: "The consultation has generated an unprecedented response. We estimate that 20,000 people have expressed their horror at the NICE proposals to deny people sight saving treatment.
"When the public speaks in this way, NICE simply cannot ignore it."
Chair of the AMD Alliance International Don Curran lives with the condition himself and adds that it is "never too late to ensure others don't share the same fate."
NICE are expected to issue their final decision on funding this autumn.